AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.93
+1.29%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.66
From 52W high−40.63%
Volume1.10M
Market cap$493.26M
P/E (TTM)—
P/S (TTM)9.1x
Div yield—
Key dataNov 4, 2026
Open
$3.66
From 52W high
−40.63%
Volume
1.10M
Market cap
$493.26M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.4x
P/E (TTM)
—
RSI (14)
37.9
MomentumView details →
1D Return
+1.29%
YTD Return
−40.45%
SummaryUpdated Sep 1, 2026
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a specialty pharmaceutical company founded in 2004 and headquartered in Warren, New Jersey. The company went public in July 2018 and focuses on developing and commercializing innovative drug delivery technologies, particularly through its proprietary oral soluble film platform. Aquestive has evolved from a contract manufacturing organization into a fully integrated pharmaceutical company with both commercial products and a robust pipeline of proprietary drug candidates targeting various therapeutic areas including epilepsy, anaphylaxis, ADHD, and rare diseases.
Similar companies
Latest newsMore news →
Aquestive Therapeutics, Inc. reported a third-quarter loss of $0.13 per share, compared with a loss of $0.14 per share a year earlier.17h agoAquestive Therapeutics reported third-quarter 2026 revenue of $7.6 million, a net loss of $16.5 million and diluted loss per share of $0.13.18h agoInovio Pharmaceuticals, Aquestive Therapeutics, X4 Pharmaceuticals and Jazz Pharmaceuticals saw unusually high options volume.1d ago